UBS AM
KRTX

UBS AM’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

UBS AM’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-140,675
Closed -$44.5M – 2579
2023
Q4 		$44.5M Sell
140,675
-17,189
-11% -$3.34M 0.02% 619
2023
Q3 		$26.7M Buy
157,864
+20,886
+15% +$3.93M 0.01% 705
2023
Q2 		$24.9M Hold
136,978
– – 0.01% 719
2023
Q1 		$24.9M Buy
136,978
+28,166
+26% +$5.39M 0.01% 719
2022
Q4 		$21.4M Buy
108,812
+3,259
+3% +$699K 0.01% 739
2022
Q3 		$23.7M Sell
105,553
-59,156
-36% -$12M 0.01% 722
2022
Q2 		$20.8M Sell
164,709
-78,517
-32% -$9.02M 0.01% 727
2022
Q1 		$30.8M Buy
243,226
+2,783
+1% +$313K 0.01% 728
2021
Q4 		$31.5M Buy
240,443
+23,880
+11% +$3.09M 0.01% 784
2021
Q3 		$26.5M Sell
216,563
-13,314
-6% -$1.54M 0.01% 800
2021
Q2 		$26.2M Sell
229,877
-538
-0.2% -$62.9K 0.01% 816
2021
Q1 		$27.7M Sell
230,415
-18,010
-7% -$2.04M 0.01% 786
2020
Q4 		$25.2M Buy
248,425
+23,658
+11% +$2.19M 0.01% 786
2020
Q3 		$17.4M Sell
224,767
-234
-0.1% -$19.9K 0.01% 812
2020
Q2 		$25.1M Buy
225,001
+65,578
+41% +$5.7M 0.02% 676
2020
Q1 		$11.5M Buy
+159,423
New +$13.6M 0.01% 822

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

UBS AM's KRTX Position: Q1 2024 in Review

UBS AM sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 140,675 shares — an estimated $44.5M sold.

UBS AM first reported a position in KRTX in Q1 2020 and held it in 16 quarters. The position peaked at $44.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • UBS AM reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS AM sold 140,675 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $44.5M.
  • UBS AM first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
  • UBS AM's Karuna Therapeutics, Inc. Common Stock position peaked at $44.5M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.